偏头痛是一种常见的致残性的原发性头痛，给患者、家庭和社会均带来显著的经济负担。偏头痛的管理涉及多个方面，包括急性期治疗和预防性治疗。非甾体抗炎药是轻至中度偏头痛发作的一线治疗选择；而对于中至重度发作的偏头痛和慢性偏头痛，曲普坦类和预防性治疗是必要的。降钙素基因相关肽（calcitonin gene-related peptide，CGRP）在偏头痛的发病机制中具有重要作用，并促成了CGRP拮抗剂以及针对偏头痛发作时释放的CGRP及其目标受体的单克隆抗体的研发。最近，有数种抗CGRP或其受体的单克隆抗体经美国食品药品监督管理局批准上市，用于治疗发作性和慢性偏头痛。迄今为止，偏头痛的发病机制尚不明确。本文旨在对偏头痛发病机制和治疗新进展进行综述，尤其关注于偏头痛预防性治疗策略中抗CGRP单克隆抗体的潜在作用。

Migraine is a common and disabling primary headache disorder, which brings significant economic burden to patients, families and society. The management of migraine is multifaceted, including acute treatment and preventive strategy. Non-steroidal antiinflammatory drugs are first-line treatment for mild to moderate migraine attacks, while triptans and preventive treatment are needed for moderate to severe migraine and chronic migraine attacks. Calcitonin gene-related peptide (CGRP) plays an important role in the pathogenesis of migraine, and promotes the development of CGRP antagonists and monoclonal antibodies against circulating CGRP which is released during migraine attacks or targeting its receptor. Recently, several monoclonal antibodies against CGRP or its receptors have been approved by the Food and Drug Administration of the United States for the treatment of episodic and chronic migraine. So far, the pathogenesis of migraine is not clear. The purpose of this paper is to review the progress in the pathogenesis and treatment of migraine, with particular attention to the potential role of anti-CGRP monoclonal antibodies in the prophylaxis of migraine.